ESMO 2023 movers – who won and who lost?
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
ESMO 2023 – Padcev hits its home run
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.
ESMO 2023 – not so fast, Welireg
The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.
ESMO 2023 – Perla gives Jemperli combos more backing
The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.
After failing to get Seagen Merck turns to Daiichi
In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.
